FDA's Woodcock says bills wouldn't be a quick fix

03/15/2012 | BioCentury

The FDA and BIO agree that pending legislation would expand the scope of the accelerated drug approval program, but FDA Center for Drug Evaluation and Research Director Janet Woodcock says the results may not be immediate. "The real problem is the paucity of worked-up endpoints, either as surrogates or as clinical endpoints that could be used for accelerated approval," she said. Alnylam Pharmaceuticals CEO John Maraganore said progress is needed "when it comes to FDA accepting clinical endpoints" and that Congress can help by making it clear that it wants greater use of the accelerated approval process.

View Full Article in:

BioCentury

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX